HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 22, No 11, November 2018 – The Asian Cancer - War on liver cancer       » 2018 Nobel Prize in Physiology or Medicine winners       » Women more prone to selected chemotherapy side effects       » Tibetan fungus could help fight liver cancer       » Standards for TCM decoction to be applied globally       » RMB200 million donation to build Tsinghua University Biomedical Sciences Building      
INSIDE INDUSTRY
A new treatment to lose weight and keep it off
Novo Nordisk launches a new obesity treatment: Saxenda

A new injectable medicine is in the market to help overweight and obese people lose weight. Novo Nordisk’s Saxenda (liraglutide 3.0 mg) is a once-daily glucagon-like peptide-1 (GLP-1) analogue with 97 percent similarity to naturally occurring human GLP-1, a hormone that is released in response to food intake. Saxenda regulates appetite by increasing feelings of fullness and satiety, while lowering feelings of hunger and prospective food consumption, thereby leading to lower calorie intake and weight loss.

Saxenda when used alongside a low-calorie meal plan and increased physical activity, helps adults with obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2 to <30 kg/m²) with at least one weight-related medical problem (such as high blood pressure, high cholesterol, or type 2 diabetes or, prediabetes, or obstructive sleep apnea) to lose weight.

As with other GLP-1 receptor agonists, Saxenda stimulates insulin secretion and lowers glucagon secretion in a glucose-dependent manner. These effects can lead to a reduction of fasting and post-prandial blood glucose for those with diabetes.

The efficacy of Saxenda as a weight loss agent has been conducted in four clinical trials involving more than 5000 patients. Saxenda has been approved by Health Sciences Authority (HSA), Singapore. It is also approved by the US Food and Drug Administration (FDA) and the European Commission (EC).

Saxenda is available in 33 countries, including Australia, South Korea, US and UK.

Click here for the complete issue.

NEWS CRUNCH  
news Asia is the fastest growing region for nutraceuticals
news 2018 Nobel Prize in Physiology or Medicine winners
news Vitafoods Asia expands by 40 per cent in 2018
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Women in Science - Making a difference
April:
Digestive health in the 21st century - Trust your guts
May:
Dental health - The root to good health
June:
Cancer - Therapies and strategies for better patient outcomes
July:
Water management - Technologies for biotech and pharmaceutical industries
August:
Regenerative technology - Meat of the future
September:
Doctor Robot - The digital healthcare revolution
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy